General Medicine News and Research

RSS

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use recommended Xofigo (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

20 Sep 2013

Researchers discover how Yersinia immobilizes immune system to spread within organs

Researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts have identified how one type of bacteria, Yersinia, immobilizes the immune system in order to grow in the organs of mice. To do so, the researchers extended the use of a technique and suggest that it could be used to study other bacteria that use the same or similar means of infection.

17 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

Research roundup: Assessing new hospital observation rule; doctors' view of DNR orders for kids

Hospitalized patients in the United States are increasingly placed on "observation status." The Centers for Medicare & Medicaid Services (CMS) state that observation should rarely exceed 48 hours.

31 Aug 2013

European Commission approves Stivarga tablets for treatment of patients with mCRC

Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the European Commission has approved Stivarga® (regorafenib) tablets for the treatment of adult patients with metastatic colorectal cancer (mCRC).

30 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

USPSTF recommends clinicians provide interventions to prevent tobacco use in children

The United States Preventive Services Task Force (USPSTF) recommends that primary care clinicians provide interventions, including education or brief counseling, to prevent initiation of tobacco use in school-aged children and adolescents.

26 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

Pre-doctoral students receive International Student Research Fellowships from HHMI

The Howard Hughes Medical Institute has awarded two doctoral students from the Sackler School of Graduate Biomedical Sciences at Tufts University with 2013 International Student Research Fellowships. Seblewongel Asrat, from Ethiopia, studies the bacterium that causes Legionnaires' disease while Jennifer Nwankwo, from Nigeria, studies red blood cell dehydration in sickle cell disease.

17 Aug 2013

Absence of Shp-2 enzyme near cartilage cells can lead to multiple benign cartilage tumors in mice

Rhode Island Hospital researchers have found that the absence of the Shp-2 enzyme near specialized cartilage cells can lead to the development of multiple benign cartilage tumors in mice, a model that recapitulates the rare human tumor syndrome metachondromatosis.

20 Jul 2013

New book examines links between violence against women and mental health

The book, written and supported by international leaders in mental health and women's issues, provides the first comprehensive overview on this crisis, examining the links between violence against women and mental health and the underlying causes, as well as the implications of these findings for mental health policies and programs.

18 Jul 2013

Study shows very few physicians follow HPV and cervical cancer prevention guidelines

Recent breakthroughs in cervical cancer prevention have resulted in new vaccination and cervical cancer screening guidelines. Recommendations do not always translate into practice, however.

9 Jul 2013

Bayer starts enrollment in BAY94-9027 Phase II/III trial for hemophilia A in children

Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A in children.

8 Jul 2013

Wake Forest Baptist to extend innovation in geriatrics education with new GPS program

Wake Forest Baptist Medical Center will maintain its position as a leader in geriatric medicine and medical training with continued grant funding from the Donald W. Reynolds Foundation.

3 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

UCSF scientists explore how Dact1 mutations contribute to psychiatric disorders

Gene mutations that cause cell signaling networks to go awry during embryonic development and lead to major birth defects may also cause subtle disruptions in the brain that contribute to psychiatric disorders such as schizophrenia, autism, and bipolar disorder, according to new research by UC San Francisco scientists.

25 Jun 2013

Study finds middle-aged women experience stress associated with psychosomatic symptoms

In four out of ten cases, long-term stress suffered by women leads to some form of physical complaint. This is shown by a study of 1,500 women carried out at the Sahlgrenska Academy, University of Gothenburg, Sweden.

4 Jun 2013

Improved communication could help with end of life decision making, suggests BIDMC research

In any given year, 400,000 Americans suffering from end-stage kidney disease will undergo dialysis, and as many as 20 to 25 percent of those dialysis patients will die, a statistic comparable to many types of cancer.

28 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013